# Table of Contents

**Pediatrics** .......................................................... 1-3

Sepsis and Meningitis; Respiratory Syncytial Virus Infection; Otitis Media; Immunizations; Pediatric Seizure Disorders; Attention-Deficit/Hyperactivity Disorder

**Geriatrics** ............................................................. 1-39

Principles to Promote Optimal Medication Use in Older People; Dementia; Behavioral Symptoms of Dementia; Urinary Incontinence; Benign Prostatic Hypertrophy; Osteoarthritis; Rheumatoid Arthritis

**Neurology** .............................................................. 1-83

Epilepsy; Ischemic Stroke; Parkinson Disease; Headache; Multiple Sclerosis

**General Psychiatry** ................................................ 1-145

Depression; Bipolar Disorder; Schizophrenia; Anxiety Disorders; Insomnia; Substance Use Disorders

**Endocrine and Metabolic Disorders** ............................. 1-203

Thyroid Disorders; Pituitary Gland Disorders; Adrenal Gland Disorders; Obesity; Polycystic Ovary Syndrome; Diabetes Mellitus and Insipidus; Treatment of DM Complications; Other Diabetes Medication Issues

**Nephrology** .............................................................. 1-261

Acute Kidney Injury (AKI) or Acute Renal Failure (ARF); Drug-Induced Kidney Damage; Chronic Kidney Disease; Renal Replacement Therapy (RRT); Managing the Complications of Chronic Kidney Disease; Dosage Adjustments in Kidney Disease

**Fluids, Electrolytes, and Nutrition** ............................... 1-307

Fluid Management; Osmolality; Hypertonic Saline; Hypotonic Intravenous Fluids; Hyponatremia and Hypo-osmolal States; Hypernatremia and Hyperosmolar States; Disorders of K⁺; Disorders of Magnesium Homeostasis; Disorders of Phosphorus Homeostasis; Disorders of Calcium Homeostasis; Enteral Nutrition; Parenteral Nutrition

**Biostatistics: A Refresher** ........................................... 1-357

Introduction to Statistics; Types of Variables and Data; Types of Statistics; Population Distributions; Confidence Intervals; Hypothesis Testing; Statistical Tests; Decision Errors; Correlation and Regression; Survival Analysis; Selected Representative Statistical Tests
## STUDY DESIGNS: FUNDAMENTALS, INTERPRETATION, AND RESEARCH TOPICS .... 1-381

Various Issues in Study Design; Case Reports and Case Series; Observational Study Designs; Incidence, Prevalence, Relative Risks or Risk Ratios, and Odds Ratios; Randomized Controlled Trial Design; Other Issues to Consider in Controlled Trials; Controlled Clinical Trials: Analyzing Clinical Trials; Systematic Review and Meta-analysis; Summary Measures of Effect; Reporting Guidelines for Clinical Studies; Pharmacoeconomic Studies; Sensitivity/Specificity/Predictive Values; Institutional Review Board/Human Subjects' Research; Professional Writing: The Publication Process

## MEN'S AND WOMEN'S HEALTH ................................................................. 1-415

Hormone Therapy/Menopause; Osteoporosis; Drugs in Pregnancy; Drugs in Lactation; Complications in Pregnancy; Contraception; Menstrual Disorders; Infertility; Sexually Transmitted Infections; Prostatic Infections; Sexual Dysfunction

## CRITICAL CARE .................................................................................. 1-499

Interpretation of Hemodynamic Parameters; Treatment of Shock; Interpretation of Acid-Base Disturbances; Acute Respiratory Failure; Cardiac Arrest; Pain, Agitation, Delirium, and Neuromuscular Blockade; Glucose Control; Preventing Stress Ulcers; Pharmacologic Therapy for Preventing Venous Thromboembolism; Preventing Ventilator-Associated Pneumonia; Nutritional Support in Critically Ill Patients

## PHARMACOKINETICS: A REFRESHER .................................................. 1-557

Basic Pharmacokinetic Relationships; Absorption; Distribution; Clearance; Nonlinear Pharmacokinetics; Noncompartmental Pharmacokinetics; Data Collection and Analysis; Pharmacokinetics in Renal Disease; Pharmacodynamics

## PULMONARY DISORDERS, GOUT, AND ADULT IMMUNIZATIONS .......... 1-595

Asthma; Chronic Obstructive Pulmonary Disease; Gout; Adult Immunizations
# Table of Contents

## Cardiology I

Acute Coronary Syndromes; Acute Decompensated Heart Failure; Acute Arrhythmias/Advanced Cardiac Life Support; Hypertensive Emergency; Pulmonary Arterial Hypertension

## Cardiology II

Heart Failure; Atrial Fibrillation; Hypertension; Dyslipidemia; CHD and Chronic Stable Angina

## Oncology Supportive Care

Antiemetics; Pain Management; Treatment of Febrile Neutropenia; Use of CSFs in Neutropenia and Febrile Neutropenia; Thrombocytopenia; Anemia and Fatigue; Chemoprotectants; Oncology Emergencies; Miscellaneous Antineoplastic Pharmacotherapy

## Gastrointestinal Disorders

Gastroesophageal Reflux Disease (GERD); Peptic Ulcer Disease; Upper GI Bleeding; Inflammatory Bowel Disease (IBD); Complications of Chronic Liver Disease; Viral Hepatitis; Nausea and Vomiting; Pancreatitis; Diarrhea; Constipation; Irritable Bowel Syndrome

## Infectious Diseases

Respiratory Tract Infections; Urinary Tract Infections; Skin and Soft Tissue Infections; Osteomyelitis; Central Nervous System Infections; Endocarditis; Intra-abdominal Infections; Clostridium difficile Infection; Medical/Surgical Prophylaxis

## HIV/Infectious Diseases

Human Immunodeficiency Virus; Opportunistic Infections in Patients with HIV; Tuberculosis; Antifungal Therapy

## Policy, Practice, and Regulatory Issues

Institutional Medication Use Policy Considerations; Congressional Overview, Committees with Jurisdiction over Health-Related Policy, and the Legislative Process; U.S. Government Departments and Agencies with Primary Regulatory Impact on the Practice of Pharmacy; Accrediting Organizations and Quality Improvement Efforts; the U.S. Food and Drug Administration and the Prescription Drug Approval Process; Institutional Review Board Implications for Clinical Practice and Research; Investigational Drug Service

## Economic and Patient-Reported Outcomes Assessment

Outcomes; Cost; Perspective; Components of Pharmacoeconomic Analyses; Pharmacoeconomic Evaluations; Patient-Reported Outcomes
ADDITIONAL RESOURCES

PRACTICES AND PROCESSES OF CARE/ORGANIZATIONAL AGREEMENTS/
SPECIAL ISSUES IN PHARMACY PRACTICE ........................................... 2-447

Scopes of Practice; Pharmaceutical Care; Medication Therapy Management; Comprehensive Medication Management; Collaborative Drug Therapy Management; Credentialing and Privileging; Pharmacists’ Patient Care Process; Transitions of Care; Medication Reconciliation; Immunizations; Point-of-Care Testing; Patient Assistance; Medication Safety; Pharmacy and Therapeutics Committees and Formulary Management; Medicare Part D

COMMUNICATION STRATEGIES IN PHARMACY .......................... 2-519

Communicating Verbally with Patients and Caregivers; Selecting Written Patient Educational Materials; Alternative Methods of Communicating with Patients; Communicating with Other Health Care Professionals; Documenting in the Medical Record; Opportunities for Patient Advocacy Outside the Health Care System

PRINCIPLES AND METHODS OF EDUCATING HEALTH CARE PROFESSIONALS .... 2-565

Evidence Supporting Teaching, Precepting, and Learning; Current Educational Frameworks and Guiding Philosophies; Designing Instruction to Achieve Learning Outcomes; Additional Thoughts on Role Modeling and Mentoring; Knowledge and Skill Assessment Techniques

MANAGING A CLINICAL PRACTICE ..................................................... 2-595

General Ongoing Management; Determining How You Will Communicate; Establish a Standard Process for Documentation; Measuring the Quality of Your Program; Ensuring the Continued Competency of Your Staff; Reimbursement for Pharmacist Services in the Ambulatory Setting; Sustaining Your Practice for the Future

DRUG INFORMATION RESOURCES AND LITERATURE RETRIEVAL .......... 2-653

Overview of Drug Information Resources; Internet Sources of DI; Evaluating DI Resources; Accessing Quality DI Resources; Specific DI Resources

THE BOARD OF PHARMACY SPECIALTIES “2017 RECERTIFICATION GUIDE” ...... 2-681

Printed courtesy of the Board of Pharmacy Specialties